Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
30.31
-1.03 (-3.29%)
May 18, 2026, 11:19 AM EDT - Market open
Celldex Therapeutics Revenue
Celldex Therapeutics had revenue of $15.00K in the quarter ending March 31, 2026, a decrease of -97.84%. This brings the company's revenue in the last twelve months to $866.00K, down -88.54% year-over-year. In the year 2025, Celldex Therapeutics had annual revenue of $1.55M, down -77.99%.
Revenue (ttm)
$866.00K
Revenue Growth
-88.54%
P/S Ratio
2,843.86
Revenue / Employee
$4,369
Employees
198
Market Cap
2.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55M | -5.48M | -77.99% |
| Dec 31, 2024 | 7.02M | 136.00K | 1.98% |
| Dec 31, 2023 | 6.88M | 4.53M | 192.07% |
| Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
| Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
| Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
| Dec 31, 2019 | 3.57M | -5.97M | -62.54% |
| Dec 31, 2018 | 9.54M | -3.21M | -25.15% |
| Dec 31, 2017 | 12.74M | 5.96M | 87.78% |
| Dec 31, 2016 | 6.79M | 1.31M | 23.83% |
| Dec 31, 2015 | 5.48M | 1.89M | 52.82% |
| Dec 31, 2014 | 3.59M | -525.00K | -12.77% |
| Dec 31, 2013 | 4.11M | -7.09M | -63.30% |
| Dec 31, 2012 | 11.20M | 1.94M | 20.91% |
| Dec 31, 2011 | 9.27M | -37.53M | -80.20% |
| Dec 31, 2010 | 46.79M | 31.61M | 208.25% |
| Dec 31, 2009 | 15.18M | 7.72M | 103.59% |
| Dec 31, 2008 | 7.46M | 6.05M | 430.30% |
| Dec 31, 2007 | 1.41M | 506.82K | 56.36% |
| Dec 31, 2006 | 899.18K | -2.19M | -70.88% |
| Dec 31, 2005 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 670.00M |
| Zai Lab | 453.28M |
| IDEAYA Biosciences | 225.27M |
| Nektar Therapeutics | 55.63M |
| Nanobiotix | 38.27M |
| Relay Therapeutics | 10.68M |
| Immunome | 4.02M |
CLDX News
- 5 days ago - Celldex price target raised to $54 from $38 at Wells Fargo - TheFly
- 9 days ago - Celldex price target raised to $38 from $34 at Goldman Sachs - TheFly
- 10 days ago - Celldex price target raised to $48 from $45 at Barclays - TheFly
- 10 days ago - Celldex sees funds sufficient to fund current planned operations through 2028 - TheFly
- 10 days ago - Celldex Reports First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX) - TipRanks
- 4 weeks ago - Celldex upgraded to Overweight from Underweight at Barclays - TheFly
- 4 weeks ago - Celldex Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Transcripts